The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

Pfizer anticipates billions less in revenue this year as vaccines commercialized

Pfizer executives said the company expects a significant drop in revenue in 2023 compared to 2022 as the U.S. government ends its purchase agreement for COVID-19 vaccines and treatments. During its 2022 fourth-quarter earnings call Tuesday, CEO Albert Bourla said he anticipates 2023 to be a “transition year” as advance government purchases end and the…

Moderna’s stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023

Moderna Inc.’s shares were down 2.8% in trading on Tuesday. Pfizer Inc. which makes a competing COVID-19 vaccine to Moderna’s Spikevax, on Tuesday put out...

'Plundered health systems for profit': Pfizer reports staggering $100 billion in revenue in 2022

The U.S.-based pharmaceutical giant Pfizer reported Tuesday that it brought in a record-breaking $100.3 billion in revenue in 2022 and $31.4 billion in profit, sums that campaigners decried as "sickening" in the face of an ongoing pandemic and persistent inequities in coronavirus vaccine access."In one year alone, Pfizer's revenue has exceeded the total health expenditures of more than 100 countries combined," Julia Kosgei, policy co-lead for th…

Pfizer projects sharp fall in Covid vaccine and treatments this year

Pfizer has forecast a bigger-than-expected drop in sales of its Covid-19 vaccine and treatment for 2023, intensifying investor concerns over demand ...

Pfizer, the first pharmaceutical company with a turnover of more than 100 billion a year

The Covid-19 vaccine boosts the revenues and profits of the New York giant

The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

Sales of Paxlovid surged to $18.9 billion in 2022 which was the first full-year that the antiviral pill was available.